Endothelin is a newly discovered, potent vasoconstrictor peptide secreted by endothelial cells. The binding of endothelin was studied on cultured human vascular smooth muscle cells obtained from umbilical veins. A single specific binding site for 125I-endothelin was identified, with an apparent Kd of 126 pM and a maximal binding capacity of approximately 10,000 sites per smooth muscle cell. At room temperature the binding was saturable, reached equilibrium at 2 h (using 20 pM endothelin), and was slowly and only partially reversed by unlabeled endothelin. The calcium antagonists nifedipine, nicardipine, and diltiazem did not compete for the same binding site. Conditioned medium from cultured human umbilical vein endothelial cells inhibited the binding of 125I-endothelin dose dependently. This effect was antagonized by anti-endothelin antiserum. We conclude that human umbilical vein smooth muscle cells possess specific binding sites for endothelin, and that human endothelial cells secrete an endothelinlike material.
Introduction
Endothelin is a potent vasoconstrictor peptide secreted by endothelial cells (1) . Human endothelin, cloned from a placenta cDNA library, and porcine endothelin, isolated from supernatant of cultured porcine endothelial cells, have identical sequences (2) .
Endothelin is a 21 amino acid peptide with two disulfide bridges that cannot be placed in any known family among the mammalian peptides, but has a strong homology with sarafotoxin S6, a group of 21-residue cardiotoxic peptides isolated from snake venom (3) . Since it had also some homology with neurotoxins acting on tetrodotoxin-sensitive Na+ channels, which resemble the dihydropyridine-sensitive Ca2+ channels, and since the vasoconstrictor activity of endothelin was inhibited by nicardipine, it was suggested that endothelin might be an endogenous agonist of the dihydropyridine-sensitive Ca2+ channels (1) . In the present study we have identified and characterized specific binding sites for endothelin on anti-a-smooth muscle cell actin antibody was a kind gift of Dr. G. Gabbiani (University of Geneva, Geneva, Switzerland), and fluorescein-conjugated goat anti-mouse antibody was from Dakopatts (Glostrup, Denmark). Nifedipine (Sigma Chemical Co., St. Louis, MO) was dissolved in ethanol to a 10-2 M solution; nicardipine and diltiazem (Roche, Basle, Switzerland) were dissolved in DMSO. Further dilutions were made in DME. Care was taken to protect nifedipine-and nicardipine-containing solutions from light.
For immunoprecipitation, anti-endothelin rabbit antiserum was obtained from Peptide Institute (Osaka, Japan) and Immunobead Second Antibody Reagent from Bio-Rad Laboratories (Richmond, CA).
Cell culture. Human endothelial cells were obtained from umbilical veins and cultured as described by Jaffe (4) . The cells were harvested after the vein had been filled for 12 min with collagenase (2 mg/ml) in HBSS. They were grown to confluence on plastic flasks in RPMI 1640 supplemented with 20% FCS in a volume of -1 ml for 2 X 105 cells.
The conditioned medium was collected every 48 h. Conditioned medium was centrifuged (1,000 g, 10 min) and concentrated by extraction through a C18 Sep-Pak cartridge conditioned with acetonitrile containing 5 mM trifluoracetic acid. The retained material was eluted with methanol, evaporated, and resuspended in binding medium. The volumes given in the text and figures are the volumes of conditioned medium before extraction.
Human vascular smooth muscle cells were obtained and cultured as described (4, 5) . Briefly, after a first incubation with collagenase to remove endothelial cells, the umbilical vein was filled again with collagenase for 45 min. Smooth muscle cells were grown to confluence in plastic flasks or 24-well plates in DME supplemented with 10% FCS.
Smooth muscle cells were subcultured after trypsinization (the cell detachment after trypsin-EDTA was followed by microscopy and the trypsin was immediately neutralized by adding DME + 10% FCS). The cells were used between passages 4 and 6. They were identified by their typical "hill-and-valley" morphology and by immunofluorescence using a MAb against a-smooth muscle actin, which is a specific marker of differentiated smooth muscle cells (6) . Fluorescein-conjugated goat anti-mouse antibody was used as a second antibody. All the cells were labeled by the antibodies (Fig. 1) (3.3 mg/500 ql of 1:1,000 dilution of antiserum) and incubated for 2 h at 370C. The immune complexes were precipitated by centrifugation (7 min at 1,000 g) and the supernatant was used in competition experiments. Competition experiments with conditioned medium that had not been treated with antiserum were performed in parallel.
Results
Kinetics ofthe binding. The binding of I251-endothelin to cultured human smooth muscle cells reached an apparent equilibrium after 2 h (Fig. 2 A) . In all subsequent experiments, therefore, the incubation time of smooth muscle cells with labeled endothelin was 2 h. The binding of '251-endothelin was only partially reversed by addition of 10 IAM unlabeled endothelin. At 24 h the binding of '251-endothelin was still 53% of maximal binding (Fig. 2 B) . The dissociation of '251-endothelin displayed a biphasic curve when analyzed by logarithmic transformation and linear regression. Typical estimates of fast and slow dissociation half-lives were 5 and 69 h, respectively.
Saturation experiments. The specific binding of '251-endothelin to smooth muscle cells was saturable, as shown in Fig.  3 . Scatchard analysis indicated the existence ofa single population of binding sites. The calculated equilibrium Kd was 126 pM and the maximal binding capacity was 16.9 fmol/106 cells, i.e., 10,180 binding sites per cell.
Competition experiments. The binding of '251-endothelin was inhibited by unlabeled endothelin, with a half-maximal inhibition concentration of 212 pM (Fig. 4) . Conditioned medium from cultured human endothelial cells also completely inhibited 1251-endothelin binding (Fig. 4) . The volume of conditioned medium (before extraction) that inhibited the binding by 50% was 270 Al. Thus, the concentration of endothelinlike material in conditioned medium from endothelial cells could be calculated to be -395 pM, or 1 ng/ml. To evaluate whether the factor in conditioned medium that competed with 125i-endothelin for binding was immunologically related to endothelin, immunoprecipitation with anti-endothelin rabbit antiserum and Immunobead Second Antibody was performed. After immunoprecipitation, the supernatant of conditioned medium up to a volume of 200 ,ul did not compete with the binding of 1251-endothelin (Fig. 4) .
The binding of 125I-endothelin was inhibited neither by nifedipine, nicardipine, nor diltiazem when added in concentrations up to 10 ,M (Fig. 5) . 
Discussion
The results of the present study show that human vascular smooth muscle cells cultured from umbilical veins possess a single class of specific binding sites for endothelin. The binding of endothelin to human cultured smooth muscle cells is of high affinity, specific, and saturable within 2 h. The dissociation of labeled endothelin after addition of unlabeled endothelin is biphasic. The second and slow phase might be due to a very tight binding and/or internalization of the receptor.
Endothelin is able to constrict human mesenteric and pulmonary arteries (1) . In the present study we '2 +a channels (1) .
Endothelin has been isolated from supernatant of porcine aortic endothelial cells (1) , and its existence has been suggested in supernatants of bovine aortic endothelial cells (8, 9) . Conditioned medium (ml) Human endothelin has finally been cloned from a placenta cDNA library (2) . However, the secretion of endothelin by human endothelial cells has not been reported until now. We present here the first argument for the presence of an endothelinlike, immunoprecipitable material in conditioned medium of cultured human endothelial cells. While we were performing this study a paper was published on the specific binding of endothelin on rat vascular smooth muscle cells in culture (10) . Endothelin binds to these cells with an apparent Kd of 200-400 pM and a maximal binding capacity of 1 1,000-13,000 sites/cell. This suggests a close homology between human and rat smooth muscle cell receptor for endothelin.
In conclusion, endothelin binds specifically to human vascular smooth muscle cells. The binding site is distinct from the dihydropyridine binding site. The mechanisms involved in the potent vasoconstrictor effect of endothelin are still to be identified. 
